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Mutations in the gene encoding profilin 1 (PFN1) have recently been shown to cause amyotrophic lateral
sclerosis (ALS), a fatal neurodegenerative disorder. We sequenced the PFN1 gene in a cohort of ALS
patients (n ¼ 485) and detected 2 novel variants (A20T and Q139L), as well as 4 cases with the previously
identified E117G rare variant (w 1.2%). A case-control meta-analysis of all published E117G ALSþ/
frontotemporal dementia cases including those identified in this report was significant p ¼ 0.001, odds
ratio ¼ 3.26 (95% confidence interval, 1.6e6.7), demonstrating this variant to be a susceptibility allele.
Postmortem tissue from available patients displayed classic TAR DNA-binding protein 43 pathology. In
both transient transfections and in fibroblasts from a patient with the A20T change, we showed that this
novel PFN1 mutation causes protein aggregation and the formation of insoluble high molecular weight
species which is a hallmark of ALS pathology. Our findings show that PFN1 is a rare cause of ALS and adds
further weight to the underlying genetic heterogeneity of this disease.
Crown Copyright  2015 Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Amyotrophic lateral sclerosis (ALS) is a typically late onset,
neurodegenerative disorder characterized by the degeneration of
large motor neurons of the brain and spinal cord, resulting in death
on average within 3 years of symptom onset. Five to 10 percent of
patients have a family history of ALS and/or frontotemporal de-
mentia. Mutations in 4 major genes: SOD1, TARDBP, FUS, and the
intronic GGGGCC expansion within C9ORF72 account for approxi-
mately 60% of familial (FALS) and approximately 10% of sporadic ALS
(SALS) cases (Al-Chalabi et al., 2012). Recently, missensemutations in
profilin1 (PFN1) were identified in 2 large ALS families by exome
capture and next generation sequencing, and screening of a larger
cohort identified 7 further mutations in 274 FALS casesClinical Neuroscience, PO43,
, Kings Health Partners, De
5180; fax: þ44 207 848 0988.
haw).
ticle.
vier Inc. This is an open access art(approximately 2.5%) (Wu et al., 2012). An additional 10 reports of
PFN1 gene screens have identified only 2 novel mutations: a T109M
mutation in 1 German FALS case and a R136Wmutation in a Chinese
SALS case (Chen et al., 2013; Ingre et al., 2013). The previously
described rare dinucleotide variant encoding E117G has been iden-
tified in 15 of 5601 cases in European ALS cohorts with or without
frontotemporal dementia (FTD) (Daoud et al., 2013; Dillen et al.,
2013; Fratta et al., 2013; Lattante et al., 2012; Tiloca et al., 2012;
van Blitterswijk et al., 2013; Yang et al., 2013). See Supplementary
Table 1 for a complete list of published PFN1 mutations.
In this study, we screened a cohort of 485 UK familial and spo-
radic ALS cases for PFN1 mutations and biologically characterized
the cellular pathology of the novel variants.
2. Methods
2.1. Patient and DNA samples
Ninety-seven FALS and 215 SALS patient DNA samples from
the research DNA resource within the Clinical Neuroscienceicle under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/
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ence, King’s College London, UKwere analyzed. Consentwas provided
bypatients afterexaminationanddiagnosis of definiteorprobableALS
based on revised El Escorial criteria (Brooks, 2000) by consultant
neurologists at the Motor Neuron Disease clinic at King’s College
Hospital. DNA from an additional 3 FALS, 37 SALS/FTD, and 133 SALS
cases were sourced from the Medical Research Council London
Neurodegenerative Diseases Brain Bank. All cases were negative for
mutations in SOD1, TDP-43, FUS, the C9ORF72 expansion, VCP, OPTN,
and VAPB. DNA was extracted from white blood cells or frozen brain
tissue using standard phenol and/or chloroform extraction pro-
cedures. Nine hundred andnine local control samplesmatched for sex
and age were assayed using KASPar genotyping methods by LGC Ge-
nomics (LGC Genomics, Teddington, UK). No controls from Middle
Eastern populations were available for screening.
2.2. Genetic screening
The 3 coding exons of PFN1 (Refseq ID NM_005022.3) were
amplified using standard polymerase chain reaction procedures
including at least 100 bp of flanking intronic sequence. See
Supplementary Material for primers and cycling conditions. The
amplicons were directly sequenced with Big-Dye Terminator v1.1
on an ABI3130 genetic analyzer (Applied Biosystems Pty Ltd, War-
rington, UK). Sequence chromatograms were analyzed for muta-
tions using Sequencher 4.10 (Gene Codes Corporation, Ann Arbor,
Michigan, USA). Novel mutations were reconfirmed by amplifying a
second aliquot of stock DNA sample.
2.3. Mutation modeling and prediction of protein destabilization
Sequence-based assessment of the potential pathogenicity of
each coding variant identified was assessed by submitting the
genomic coordinates and alternate alleles to the SIFT (Ng and
Henikoff, 2001) (http://sift.jcvi.org/www/SIFT_chr_coords_submit.
html) and Provean web servers (Choi et al., 2012) (http://provean.
jcvi.org/genome_submit_2.php) and the amino acid position and
alternate residue to the PolyPhen-2 web server (Adzhubei et al.,
2010) (http://genetics.bwh.harvard.edu/pph2/). The presence of
multiple entries for the PFN1 protein in the Protein Data Bank (PDB,
www.pdb.org) database of macromolecular structures also enabled
the use of structure-based predictors of the likelihood of each
mutation destabilizing the protein. The PDB structure 2PAV was
chosen as being representative of PFN1 and submitted, along with
the amino acid position and alternate residue, to the SDM (Worth
et al., 2007) (http://mordred.bioc.cam.ac.uk/wsdm/sdm.php),
POPMUSIC-2.1 (Dehouck et al., 2011) (http://dezyme.com/), and I-
Mutant-3.0 (Capriotti et al., 2008) (http://gpcr2.biocomp.unibo.it/
cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi) web servers.
In silico mutagenesis was performed for the 3 mutations identi-
fied in this study, using the SwissModel webserver (Arnold et al.,
2006) (http://swissmodel.expasy.org/) and the PDB template struc-
ture 2PAV (http://www.pdb.org/pdb/explore/explore.do?structureId
¼2pav). All amino acid side chains in close proximity to the
mutated residues were subsequently fixed by simulated annealing in
DeepView (Johansson et al., 2012), and the final diagrams rendered
with PyMol (The PyMOL Molecular Graphics System, Version 1.5.0.4
Schrödinger, LLC). All variants identified in this study were also
assessed for changes to splicing using Netgene2 (Hebsgaard et al.,
1996) (http://www.cbs.dtu.dk/services/NetGene2/).
2.4. Meta-analysis study
A Pubmed literature search was conducted for all articles con-
taining the keywords “(PFN1 or profilin) and (ALS or amyotrophic)”.Six reports describing mutation screening of PFN1 in European
cohorts and controls (Dillen et al., 2013; Fratta et al., 2013; Tiloca et
al., 2012; van Blitterswijk et al., 2013;Wu et al., 2012) and this study
were included in a meta-analysis for E117G frequency. Three re-
ports (Daoud et al., 2013; Lattante et al., 2012; Yang et al., 2013)
were excluded as they did not include screening of local population
controls, and two reports (Chen et.al., 2013; Zou et.al., 2013) were
excluded as the E117G variant has not been observed in any East
Asian population. The meta-analysis was conducted using the
Comprehensive Meta-analysis Version 2 software (Biostat Inc.
Engelwood, NJ, USA) under both a fixed effects (Mantel-Haenszel)
and random effects model (DerSimonian Laird).
2.5. Plasmids and cloning
PFN1 expression vectors (Gateway pcDNA3.1/nV5-DEST, Invi-
trogen) encoding V5 epitope tagged PFN1wild type (WT), C71G and
E117G were used in this study (Wu et al., 2012). Site-directed
mutagenesis was performed according to the manufacturer’s pro-
tocol (Quickchange II Site-Directed Mutagenesis Kit, Stratagene)
using a V5-PFN1WT tagged pDONR221 entry clone plasmid to pro-
duce constructs harboring the novel mutants identified in this
study (c.58G > A, A20T, and c.416A > T, Q139L). The pDONR221-
PFN1 mutant constructs were then recombined with pcDNA3.1/
nV5-DEST to create the final mutant expression constructs. All
constructs were verified by DNA sequencing.
2.6. Transfection of HEK293T cells
HEK293T cells were maintained in DMEM with high glucose
plus Glutamax (Life Technologies, Paisley, UK) with 10% fetal bovine
serum,100 U/mL penicillin, and 100 mg/mL streptomycin in awater-
jacketed incubator at 5% CO2. For solubility fractionation, trans-
fections were performed in 12-well plates with 500 ng of plasmid
DNA and 1.5 mL of Fugene HD (Promega, Southampton, UK) per well,
as per the manufacturer’s protocol. For immunofluorescence,
HEK293T cells were plated at 25,000 cells/cm2 on 13 mm diameter,
1.5-mm-thickness coverslips coated with poly-D-lysine (Sigma-
Aldrich, Dorset, UK) in 24-well plates and transfected with 250 ng
of DNA and 0.75 mL of Fugene HD.
2.7. Human dermal fibroblast isolation and culture
Punch biopsies were performed and collected in DMEM with
high glucose plus Glutamax. After removal of fat tissuewith a sterile
scalpel blade, the biopsy was dissected into 0.5 mm explants. Ex-
plants were allowed to adhere to a dry flask, to which expansion
medium (DMEM with high glucose plus Glutamax, with 20% fetal
bovine serum, 1% non-essential amino acids, 100 U/mL penicillin,
and 100 mg/mL streptomycin) was added. After 5e7 days, medium
was changed to culture medium (DMEM with high glucose plus
Glutamax, with 15% fetal bovine serum, 100 U/mL penicillin, and
100 mg/mL streptomycin), cells were expanded once confluent and
then banked. For solubility analyses, fibroblasts were harvested
from confluent 6-well plates. Where used, 0.5 mM MG132 was
added to the media 24 hours before cells were harvested.
2.8. Immunofluorescence
Immunofluorescence was performed as previously described
(Vance et al., 2013). Briefly, cells were fixed with 4% para-
formaldehyde at room temperature for 10 minutes and rinsed with
phosphate-buffered saline (PBS). Cells were incubated with pri-
mary antibody overnight at 4 C, then with fluorescent secondary
antibodies for 3 hours at room temperature, all diluted in PBS with
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used at 1:500 (cat. no 46-0708, Life Technologies). Alexa Fluor goat
secondary antibody was used at 1:500 (anti-Mouse 488, cat. no
A11001, Life Technologies). After washing with PBS, the cells were
counterstainedwith DAPI (40,6-diamidino-2-phenylindole), and the
coverslips were mounted onto slides using fluorescence mounting
medium (Dako UK Ltd, Ely, UK) and left to harden overnight. Images
were acquired using a Zeiss Axiovert S100 (Carl Zeiss Ltd, Hert-
fordshire, UK) with a 63x/NA 1.25 Plan Neofluar oil immersion
objective, fitted with a CoolSnap EZ digital camera (Photometrics,
Tucson, AZ). The proportion of transfected cells containing cyto-
plasmic V5-PFN1 granules was determined by counting both the
total number of transfected cells and those with granules. Counts
were performed manually by an observer blinded to mutation
status. A minimum of 15 images taken at 20 for each construct
from 3 different experiments were counted. On average, over 700
cells were counted for each mutation in each experiment.
2.9. Fractionation of PFN1 by solubility
PFN1 was fractionated by solubility as described previously (Wu
et al., 2012), but with several modifications. Briefly, cells were
washed with cold PBS, then scraped into cold PBS containing pro-
tease inhibitors (Complete, Roche, UK) and phosphatase inhibitors
(PhosSTOP, Roche). Cells were pelleted by centrifugation at 10,000g
for 30 seconds at 4 C, and the pellets resuspended in lysis buffer
(1% NP-40, 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 10%
glycerol, 1 mM dithiothreitol) containing protease and phosphatase
inhibitors. After 30 minutes rotating at 4 C, an aliquot was taken
representing whole cell lysate. The remaining lysate was centri-
fuged at 15,800g for 20 minutes at 4 C. The supernatant was
removed and kept as the soluble fraction. The insoluble pellet was
washed with lysis buffer, recentrifuged, and then resuspended in a
4-fold smaller volume of urea-SDS buffer (NP-40 lysis buffer with
8 M urea, 3% SDS), then sonicated. This extract was then spun again
at 15,800g for 20minutes at room temperature and the supernatant
kept as the insoluble fraction. Equal volumes of 2 Laemmli buffer
(Laemmli, 1970) without bromophenol blue were added to all ali-
quots taken, and the lysate and soluble fractions (but not the urea-
containing insoluble fraction) were boiled for 20 minutes. To
enhance the detection of insoluble species in fibroblasts, the
insoluble pellet was resuspended directly in a 4-fold smaller vol-
ume of 1 Laemmli buffer and boiled.
2.10. Western blotting and densitometry analysis
Western blotting was performed as previously described
(Scotter et al., 2014). Whole cell lysate protein concentrations were
quantified using the BioRad DC Protein Assay (BioRad, Hemel
Hempstead, UK). A total of 5 mg (or equivalent liquid volume of the
soluble and insoluble fractions) was loaded per well of a 10%
NuPAGE Novex Bis-Tris gel (Life Technologies). Gels were trans-
ferred onto nitrocellulose using the iBlot (Life Technologies),
stained with Ponceau S, then blocked in TBS with 0.05% Tween 20
(TBS-T) with 5% non-fat dried milk (Sigma-Aldrich) for 30 minutes.
Blots were probed overnight at 4 Cwith primary antibody, then for
3 hours at room temperature with secondary antibodies (all in TBS-
T plus 1% non-fat dried milk). Antibodies used for blotting were V5
(mouse: cat. no. 46-0708, 1:5000, Life Technologies), PFN1 (mouse:
cat. no. SAB4100041, 1:1000 Sigma), histone H3 (rabbit: cat. no.
H0164, 1:10,000, Sigma-Aldrich), GAPDH (mouse: cat. no. G9545,
1:1000, Sigma-Aldrich), and Dylight fluorescent secondary anti-
bodies (goat anti-mouse 680 nm, cat. no. 35521,1:5000; goat anti-
rabbit 700 nm, cat. no. 35568,1:10,000, Fisher Scientific UK Ltd,
Leicestershire, UK).Blots were scanned on the Li-Cor Odyssey gel scanner (Li-Cor
Biotechnology, Cambridge, UK). Blots were then reprobed (without
stripping) for loading control proteins using the same antibody
conditions and scanning protocol. Blot images from 3 separate ex-
periments in TIF format were quantified using the ImageJ gel
analyzer tool (Image J 1.45e, NIH, Bethesda, USA, http://rsb.info.nih.
gov/ij/). Integrated band intensities for V5-PFN1 (transfected
HEK293T cells) or PFN1 (fibroblasts) were normalized for loading
(soluble fraction, GAPDH; insoluble fraction, H3), and total PFN1
protein (PFN1 in the lysate fraction), and then normalized to those
for WT PFN1.
2.11. Brain tissue collection and neuropathologic assessment
Brain and spinal cord tissues in 10% formalin-fixed, paraffin-
embedded tissue blocks were available from the Medical Research
Council London Neurodegenerative Diseases Brain Bank (Institute
of Psychiatry, King’s College London, UK). Consent for autopsy,
neuropathologic assessment, and research was obtained from all
subjects. Block taking for histologic and immunohistochemical
studies and neuropathologic assessment for neurodegenerative
diseases was performed in accordance with institutional and na-
tional guidelines.
2.12. Immunohistochemistry
Immunohistochemistry was carried out as per previously pub-
lished protocols (Maekawa et al., 2009). In brief, sections of 7 mm
thickness were cut from the paraffin-embedded tissue blocks,
deparaffinized in xylene, endogenous peroxidase was blocked by
2.5% H2O2 in methanol and immunohistochemistry performed. To
enhance antigen retrieval, sections were kept in citrate buffer for
10minutes followingmicrowave treatment. After blocking in normal
swine or rabbit serum (Dako UK Ltd), primary antibody was applied
overnight at 4 C. Following washes, sections were incubated with
biotinylated secondary antibody (Dako UK Ltd), followed by avi-
din:biotinylated enzyme complex (Vectastain Elite ABC kit, Vector
Laboratories, Peterborough, UK). Finally, sections were incubated for
10e15 minutes with 0.5 mg/mL 3,30-diaminobenzidine chromogen
(Sigma-Aldrich) in Tris-buffered saline (pH 7.6) containing 0.05%
H2O2. Sections were counterstained with Harris hematoxylin and
immunostaining analyzed using a Leica microscope (Leica, Wetzlar,
Germany). Antibodies used were PFN1 (rabbit: cat. no. AV48269,
1:500; mouse: cat. no. SAB410041, 1:500; rabbit: cat. no. P7624,
1:500, all Sigma-Aldrich), phospho-TAR DNA-binding protein 43
(TDP-43) pS409/410-2 (rabbit: cat. no. TIP-PTD-P02, 1:3500) and p62
(mouse: cat. no. 610833, 1:200, BD Biosciences).
2.13. Statistical analyses
Data handling and graphical representations were performed
using Microsoft Excel 2010 (Microsoft Corp, Redmond, WA, USA).
Statistical analyses as described in the text were performed using
SigmaPlot v. 12.5 (Systat Software Inc, GmbH, Germany). One-way
analysis of variance (ANOVA) was performed after Shapiro-Wilk
testing for normality and Bartlett testing for equal variance. Post-
test comparisons were performed against control using Dunnett
test, and pairwise comparisons were performed using Holm-Sidak
test. When normality or equal variance conditions were not met,
Kruskal-Wallis 1-way ANOVA on ranks was performed. Posttest
comparisons were performed against control using Dunnett test,
and pairwise comparisons were performed using Tukey test. Sta-
tistical significance was set at p 0.05 (*p 0.05; **p 0.01; ***p
0.001). All figures were prepared using Adobe Photoshop CS2
(Adobe Systems Inc, San Jose, CA, USA).
Table 1
PFN1 variants identified in this study
Exon Patient Phenotype D nucleotide D amino acid Local controls EVS (EA) Sex Age of onset Duration (mo) Site of onset
Exon 1 1 FALS c.58G > A p.A20T 0/909 Absent F 65 Alive Limb
Exon 3 2 FALS c.350_351AA > TG p.E117G 1/909 3/4297 M 62 30 Limb
Exon 3 3 SALS c.350_351AA > TG p.E117G 1/909 3/4297 F 54 24 Limb
Exon 3 4 SALS c.350_351AA > TG p.E117G 1/909 3/4297 M 74 38 Limb
Exon 3 5 SALS c.350_351AA > TG p.E117G 1/909 3/4297 M 67 14 Limb
Exon 3 6 SALS c.416A > T p.Q139L 0/909 Absent M 52 72 NA
Key: EVS (EA), exome variant server, European Americans; FALS, familial amyotrophic lateral sclerosis; NA, not available; SALS, sporadic amyotrophic lateral sclerosis.
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3.1. Identification of 2 novel PFN1 variants
A total of 100 FALS, 27 SALS/FTD, and 358 SALS cases (n ¼ 485)
were screened for nucleotide variants within the 3 coding exons of
PFN1 by direct Sanger sequencing. Two novel variants were iden-
tified (Table 1). The first was a novel missense variant, c.58G > A
located in exon 1 of a FALS patient of Middle Eastern ethnicity that
codes for an alanine to threonine amino acid change at residue 20
(A20T) and is fully conserved in mammals (Fig. 1). The change was
absent in 909 in-house controls and in 4299 European-American
and 2202 African-American exomes from the NHLBI Exome
Sequencing Project (ESP) (http://evs.gs.washington.edu/EVS/). No
controls from Middle Eastern populations were available to screen
for the A20T variant. Unfortunately, no DNA was available from
family members to test for segregation of this mutation with dis-
ease status.
The second novel variant, c.416A > T coding for a glutamine to
lysine change at position 139 in the C-terminus of the protein
(Q139L) was identified in exon 3 of a Caucasian sporadic ALS pa-
tient, was absent from the ESP database and 909 in-house con-
trols, and the residue position is also fully conserved within
mammals.
The previously described dinucleotide variant (c.350e351AA >
GT), coding for an E117G residue change was observed in 4
Caucasian ALS cases from our cohort (1 FALS and 3 SALS) (4/485
total cases), present once in 909 in-house controls and 3 times inFig. 1. Residue conservation of mammals and viper showing mutations identified in this stud
all mammalian species and viper. Non-mammalian species were not included because of ththe EVS (Table 1). The residue is conserved in mammals as pre-
viously described (Fig. 1).3.2. The E117G variant is an ALS risk factor
To assess whether the E117G variant is an ALS risk factor, we
reviewed all published and public domain data available from
European cohorts. Numbers for E117G positive ALS  FTD cases and
frequencies in local controls were examined. The frequency of
E117G from the ESP data set (4300 European-American samples)
was included and current as of April 2014 (http://evs.gs.
washington.edu/EVS/). We excluded all East Asian studies and
African-American controls from the ESP as E117G has only been
identified in European ALS  FTD patients and available control
datasets. All data combined yielded a total of 19 E117G positive
cases (n ¼ 6086) and 18 in controls (n ¼ 16,637); odds ratio of 2.90
and p ¼ 0.002 (Fisher exact test). We then conducted a meta-
analysis of those studies that assayed both cases and local controls
(Dillen et al., 2013; Fratta et al., 2013; Tiloca et al., 2012; van
Blitterswijk et al., 2013; Yang et al., 2013). The heterogeneity be-
tween studies was calculated using the Cochran c2-based Q-test
(p ¼ 0.962). As the heterogeneity was not significant the meta-
analysis was run under a fixed effects model (Mantel-Haenszel test)
which showed a statistically significant association OR ¼ 3.26 (95%
CI 1.6-6.8) p ¼ 0.001 (Fig. 2). A random effects model gave the same
result. This confirms and supports a recent study suggesting E117G
to be a moderate risk factor (Fratta et al., 2013).y. The residues, indicated with a red star, for A20, E117, and Q139 are fully conserved in
e lack of a clear one to one orthologous relationship in the profilin family.
Fig. 2. Meta-analysis of published E117G case-control frequencies and those identified in this study. Data are presented as a forest plot. Squares and lines correspond to the study
specific odds ratios (ORs) and 95% confidence intervals (CIs), respectively. The bottom row (filled square) shows the meta-analysis OR and CIs under fixed and random effects models.
The fixed effect model is preferred as the studies showed minimal heterogeneity (p ¼ 0.962, c2-based Q-test), although there was no difference between the two methods. The area
of the squares reflects the study specific weights (inverse of the variance). Variant counts from 4300 ESP European Americans and the 1000 Genomes project have been incorporated
into the Wu et al. (2012) control data. Studies by Yang et al. (2013), Daoud et al., 2013 and Lattante et al. (2012) did not screen local control cohorts and so did not contribute to the
final meta-analysis calculation.
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All patients harboring the A20T, Q139L, or E117G variants had
classical ALS symptoms with no evidence of FTD. The average age
of onset for these patients was 66.2 years with limb onset. The
patient carrying the A20T mutation (patient 1) is female, of
Middle Eastern ethnicity with an age of onset of 63 years, and is
still alive at the present age of 68 years (Fig. 3A). She presented
with a predominant lower motor neuron phenotype with clear
spinal onset, in the presence of upper motor neuron signs, andFig. 3. Familial gene mutations in PFN1. Pedigrees of PFN1 mutation positive cases identifi
information has been withheld and denoted by diamonds. The arrow denotes the proband of
segregation of PFN1 mutations.was wheelchair bound after 2 years. Her father presented with
symptoms of ALS at 68 years of age, and her great grandmother
was reported to have a paralysis problem occurring in her 60s.
Patient 2, who carries the p.E117G variant, was a Caucasian male
with an age of onset of 62 years and 30 months duration of dis-
ease (Fig. 3B). His mother was asymptomatic and died at the age
of 91 years. However, his maternal first cousin had ALS and died at
the age of 40 years. Clinical information on the sporadic cases
(patients 3e6) is limited with available information listed in
Table 1.ed in this study are shown for (A) A20T - Family 1 and (B) E117G - Family 2. Gender
each kindred. DNAwas unavailable from other affected and unaffected members to test
Fig. 4. Pymol rendering of novel mutations identified in this study and all published PFN1 reports. (A) A schematic diagram of PFN1 bound to VASP and actin. VASP is shown as
orange spheres, actin as purple ribbons, and PFN1 as red helices, yellow beta sheets, and green loops. Mutations identified in this study are indicated by white spheres, whereas
those described elsewhere are shown as blue spheres. BeD show the reference amino acid (left diagram) and variant amino acid (right diagram) for the A20T, E117G, and Q139L
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Fig. 5. TDP-43 immunohistochemistry in 3 cases showing PFN1 mutations. (A) TDP-43 immunopositive skein-like neuronal cytoplasmic inclusion (NCI) seen in the XIIth nerve
nucleus of the medulla (patient 2; E117G). (B) A globular TDP-43 immunopositive NCI seen in the anterior horn of the spinal cord (patient 3; E117G). (C) A TDP-43 immunopositive
glial cytoplasmic inclusion (GCI) in the spinal cord (patient 6; Q139L). No PFN1 immunopositivity was seen in any of the regions examined in any of the 3 cases. Scale bar: (A) 40 mm,
(B) 40 mm, and (C) 15 mm. Abbreviation: PFN1, profilin 1.
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Fig. 4A shows the Pymol rendered alpha-beta structure of PFN1
(PDB:2PAV) that co-crystallizes with actin (ACTA1) and the proline-
rich central portion of vasodilator-stimulated phosphoprotein
(VASP). Modeling of all published mutations and those identified in
this study demonstrates that the A20, C71, and M114 residues are
internal to the protein, and of all PFN1 mutations identified to date
these are consistently predicted to be themost damaging across the
various prediction tools (Supplementary Table 2). The A20 change
to a larger threonine creates internal conflicts at several residues,
chiefly the backbone carboxyl of the neighboring asparagine res-
idue at position 19 (Fig. 4B, T20) and would theoretically change the
conformation of the beta sheet that runs through the core of the
protein. For E117 the wild-type glutamic acid (Fig. 4C, E117)
potentially has the role of stabilizing the conformation of the
adjacent loop at residues 89e100, which the much smaller glycine
mutation (Fig. 4C, G117) would be unlikely to fulfill. The glutamine
at position 139 is the penultimate residue in the PFN1 protein chain
and lies on the external surface of the structure close to the binding
groove for the proline-rich region of VASP (Fig. 4D, Q139). However,
neither thewild type (Fig. 4D, Q139) nor themutant leucine residue
(Fig. 4D, L139) directly interact with VASP and from currently
available data it is not clear what the consequence, if any, of the
Q139 mutation might be.
3.5. Patients with PFN1 variants have classic TDP-43
neuropathology
Postmortem tissue was available from 2 patients who harbored
the E117G variant (patients 2 and 3) and also the sporadic case
carrying a Q139L change (patient 6). In all 3 cases, the right half of
the brain was available for neuropathologic examination. None of
the brains showed evidence of cerebral atrophy. In patient 2
(E117G), no spinal cord was available, but in the other 2 cases
(patients 3 and 6), there were segments of cord that showed evi-
dence of anterior nerve root thinning macroscopically.
The histology from patient 2 (E117G) revealed neuronal loss in
the XIIth nerve nucleus and motor cortex. In the XIIth nerve nu-
cleus, this was associated with neuronal cytoplasmic inclusions
(NCIs) that were positive for p62 and TDP-43 (Fig. 5A). No NCIs were
seen in the motor cortex, but both the XIIth nerve nucleus and the
motor cortex revealed glial p62 positive, TDP-43 positivemutations, respectively. The A20T mutation in the core of the protein potentially destabilizes
adjacent surface loop, whereas the surface Q139L mutation has no apparent structural im
belonging to the highlighted residue side chain which are colored according to atom (gray
from PDB: 2PAV and rendered with PyMol (The PyMOL Molecular Graphics System, Version
vasodilator-stimulated phosphoprotein.cytoplasmic inclusions. No p62 positive or TDP-43 positive in-
clusions were seen in the hippocampus, neocortex, or cerebellum.
In addition, there was Lewy body pathology (identified with a-
synuclein) confined to the brainstem. Staining with PFN1 anti-
bodies did not reveal any PFN1-positive inclusions.
The other E117G case (patient 3) showed marked loss of the
anterior horn neurons of the spinal cord and the motor neurons of
the motor cortex. Therewere p62 positive and TDP-43 positive NCIs
noted in the cord (Fig. 5B) and motor cortex, but they were rela-
tively infrequent and outnumbered by p62 positive TDP-43 positive
glial cytoplasmic inclusions (GCIs) in the cord and motor cortex.
Occasional p62 and TDP-43 positive GCIs were seen in the XIIth
nerve nucleus, but no NCIs. No Lewy Bodies were seen, and no p62
or TDP-43 positive inclusions were identified in the neocortex,
cerebellum, or hippocampus. The lateral corticospinal tracts
showed only mild loss of myelin. No PFN1 positivity was seen in
inclusion bodies. Staining with PFN1 antibodies did not reveal any
PFN1 positivity in the inclusions.
The Q139L case (patient 6) showed marked loss of the anterior
horn neurons of the spinal cord andmild neuronal loss in the motor
cortex. In the cord, there were no p62 positive or TDP-43 positive
NCIs, but there were p62 positive, TDP-43 positive GCIs (Fig. 5C).
Numerous p62 positive, TDP-43 positive GCIs were also seen in the
motor cortex, again without associated NCIs. Very occasional p62
positive NCIs were seen in the XIIth nerve nucleus, but therewas no
TDP-43 neuronal positivity, although GCIs positive for both TDP-43
and more commonly p62 were seen in this region. There was evi-
dence of moderate loss of myelin in the lateral corticospinal tracts
of the cord. No PFN1 positivity was seen in any inclusions, and no
Lewy bodies were identified.
3.6. Mutant PFN1 forms cytoplasmic granules in vitro
To assess whether the variants identified in this study showed a
pathologic cellular phenotype, V5-tagged wild type PFN1 (V5-
PFN1WT) and constructs with the A20T (V5-PFN1A20T), E117G
(V5-PFN1E117G), and Q139L (V5-PFN1Q139L) mutations identified in
our cohort were transiently transfected into HEK293Tcells (Fig. 6A).
In addition, the previously identified C71G (V5-PFN1C71G) mutation
(Wu et al., 2012) was used as a positive control. As expected, the V5-
PFNWT showed predominantly diffuse cytoplasmic localizationwith
only a small percentage of cells (0.6%) showing any granular or
punctate staining. In contrast, the V5-PFN1C71G mutant showed aa beta sheet because of steric hindrance, the E117G mutation potentially destabilizes an
pact. All PFN1 atoms are colored green, actin purple, and VASP orange, except those
¼ carbon, white ¼ hydrogen, red ¼ oxygen, blue ¼ nitrogen). All diagrams are derived
1.5.0.4 Schrödinger, LLC.). Abbreviations: PDB, protein data bank; PFN1, profilin 1; VASP,
Fig. 6. Immunocytochemistry of transfected cells shows granule accumulation ofmutant PFN1 in the cytoplasm. (A) Immunofluorescent images of HEK293Tcells expressing V5-PFN1WT,
V5-PFN1E117G, and V5-PFN1Q139L show diffuse anti-V5 staining (green). The cells expressing V5-PFN1C71G and V5-PFN1A20T show distinct punctate granular structures in the cytoplasm.
Nuclei are counterstainedwithDAPI (blue) in themerged image.Scalebar,10mm. (B)Quantificationof cells containinggranules shows that theV5-PFN1C71GandV5-PFN1A20Tconstructshave
an increased percentage of cells with granules compared with V5-PFN1WT, whereas V5-PFN1E117G and V5-PFN1Q139L are similar to the wild type (*p< 0.05). Bars represent means SEM.
Abbreviations: PFN1, profilin 1; SEM, standard error of the mean.
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distinct granules in the cytoplasm (41%, p < 0.05, Kruskal-Wallis 1-
way ANOVA on ranks with Dunnett posttest). The V5-PFN1A20T
mutant also had an increased percentage of cells with granular
staining (12%), although this did not reach significance (Fig. 6B).
This suggests that this mutation is proaggregant, but to a lesser
extent than V5-PFN1C71G. In comparison, the V5-PFN1E117G and V5-
PFN1Q139L mutations showed mainly diffuse cytoplasmic staining
with similar percentages of cells with granules to that seen for V5-
PFN1WT (both 0.7%).
3.7. Mutant PFN1 forms detergent-insoluble oligomers capable of
recruiting wild-type PFN1
The aggregated appearance of the C71G variant, as well as the
A20T variant, led us to next investigate the detergent solubility of
PFN1 mutants. Aggregated proteins often show reduced solubility
in denaturing detergent-based buffers. The V5-PFN1C71G and
V5-PFN1A20T, but not V5-PFN1E117G or V5-PFN1Q139L, variants
showed a shift in the proportions of soluble and insoluble protein
compared with V5-PFN1WT (Fig. 7A and B). The proportion of V5-
PFN1C71G and V5-PFN1A20T variant proteins which were soluble
was significantly reduced compared with V5-PFN1WT (p < 0.001, 1-
way ANOVA with Dunnett posttest). This loss of soluble protein
correlated with significantly more insoluble protein for V5-
PFN1C71G and V5-PFN1A20T than V5-PFN1WT (p < 0.05, Kruskal-
Wallis 1-way ANOVA on ranks with Dunnett posttest, Fig. 7A and C).
V5-PFN1C71G and V5-PFN1A20T also showed increased levels of
insoluble high molecular weight species (approximately 37 kDa),
which corresponded to the size of dimer between transfected V5-PFN1 (approximately 24 kDa) and recruited endogenous PFN1
(approximately 12e15 kDa). High molecular weight species of
approximately 50 kDa likely represent transfected V5-PFN1 homo-
dimer. Smears of insoluble V5-PFN1C71G and V5-PFN1A20T species of
>50 kDa may indicate oligomers. These dimers and oligomers repre-
sent hyperstable interactions, resistant to NP40 and urea solubiliza-
tion, as well as to boiling in SDS and reducing agent (dithiothreitol).
3.8. Fibroblasts from patients with the A20T variant show decreased
PFN1 solubility under stress
To determine whether mutant PFN1 was insoluble when
expressed at physiological levels, we examined endogenous PFN1
in fibroblasts grown from the patient with the A20T mutation.
These cells contain 1 wild type and 1mutant copy of the gene.With
vehicle treatment (0.01% DMSO), there was no difference in the
amount of soluble PFN1 between the A20T mutant patient fibro-
blasts and those from a control individual (1-way ANOVA with
Holm-Sidak posttest, Fig. 7D and E). Surprisingly, there was a lower
level of insoluble PFN1 in the mutant cell line in these conditions
although this did not reach significance (Kruskal-Wallis 1 way
ANOVA on ranks with Tukey posttest, Fig. 7D and F).
However, when the fibroblasts were cultured in the presence of
the proteasome inhibitor MG132, there was a significant increase in
the amount of insoluble PFN1 in the A20T cell line compared with
vehicle-treated conditions (p< 0.001, Kruskal-Wallis 1-way ANOVA
on ranks with Tukey posttest, Fig. 7D and F). Impaired proteostasis
in ALS is implicated by genetic causes of disease which affect pro-
tein degradation pathways and by the accumulation of proteins
labeled for degradation but which fail to be cleared. The addition of
Fig. 7. Fractionation of cell lysates shows that mutant PFN1 is more insoluble than the wild type. (AeC) Solubility fractionation of HEK293T cell transfected with V5-PFN1 constructs
showing lysate (L), NP-40 soluble (S), and urea soluble/NP-40 insoluble (I) fractions. The WT protein was predominantly soluble as were the E117G and Q139L proteins. Both the
C71G and A20T constructs showed significant decreases in the soluble fraction compared with the WT (***p < 0.001) alongside significant increases in the insoluble fraction (*p <
0.05). Bars represent means  SEM. There was also an increase in high molecular weight detergent resistant oligomers in the C71G and A20T insoluble fractions. (DeF) Solubility
fractionation of fibroblasts from a patient with the A20T mutation and a control individual showing lysate (L), NP-40 soluble (S), and urea soluble/NP-40 insoluble (I) fractions. PFN1
was predominantly found in the soluble fraction in both cell lines. Treatment with MG132 resulted in a significant shift of PFN1 from the soluble to the insoluble fraction in the A20T
cell line (***p < 0.001). There was no change to the solubility of PFN1 in the control line (ns ¼ nonsignificant). Bars represent means  SEM. Abbreviations: PFN1, profilin 1; SEM,
standard error of the mean; WT, wild type.
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omeric species in the A20T cell line, although not in the WT line.
This was similar to the profile seen when the A20T variant of PFN1
was overexpressed in HEK293T cells.
4. Discussion
Genetic characterizationof a local cohortofpredominantlyUKALS
cases has identified 2 novel PFN1 mutations; p.A20T (in a familial
patient) and p.Q139L as well as an additional 4 E117G variants in 1
familial and 3 sporadic patients (n ¼ 6/485, 1.2%). PFN1 mutations
therefore account for a minor proportion of ALS cases and occur at
similar mutation frequencies to VCP, OPTN, UBQLN2, and SQSTM1
mutations in CaucasianALS populations (Abramzon et al., 2012;Deng
et al., 2011; Kwok et al., 2013; van Blitterswijk et al., 2012b). We have
identified2 additional novelPFN1 variants anddemonstrated that the
A20Tmutation forms detergent resistant granules in transfected cells
anddisplays an increased tendency to aggregate inpatientfibroblasts.
Several lines of evidence suggest that the A20T mutation is
responsible for disease in patient 1. First, taking into account our own
local controls and those available from the NHLBI exome sequencing
project, the A20T mutation is absent in 5208 European control in-
dividuals and 2202 African-American exomes, which suggests this
variant is associated with ALS. As this residue is fully conserved in
mammals, an amino acid change is likely to disrupt normal protein
function. Second, in silicomodeling of the crystallized PFN1molecule
reveals that, similarly to theC71andM114 residues, theA20 residue is
internal to the protein and a larger threonine substitution is likely to
destabilize protein structure. Third, A20T PFN1 when overexpressed
in HEK293Tcells forms cytoplasmic granules, visible microscopically,
and detectable biochemically as detergent-insoluble species capable
of recruiting wild-type PFN1. Detergent resistant aggregates are a
hallmark of ALS pathology, and their formation in vitro suggests that
A20Tmayact viaa toxic gainof function involving the sequestrationof
PFN1 itself as well as interacting partners. Reduced solubility of A20T
PFN1was also seen inpatientfibroblasts treatedwith the proteasome
inhibitorMG132. An unveiling of decreased A20Tsolubility following
proteosomal inhibitionparallelswhat is seen forTDP-43 (Scotteretal.,
2014), and suggests that like TDP-43 this variant may interact with
environmental stress or the age-related decline in proteostatic sys-
tems (Gamerdinger et al., 2009; Tydlacka et al., 2008). Finally, the
presentation of symptoms of the patientwith the A20Tmutation is of
a predominant lower motor neuron syndrome, with a clear spinal
onset which conforms with previously reported familial PFN1 cases
(Ingre et al., 2013; Wu et al., 2012). This suggests that ALS patients
harboring PFN1 mutations are specific for a distinct clinical presen-
tation of symptoms.
Three sporadic patients and a familial case possess the E117G
rare variant within our ALS cohort. A meta-analysis of all published
E117G cases and frequencies from local controls and Exome Variant
Server, including our own study as a replication cohort confirmed
this association (p ¼ 0.001). This genetic evidence suggests a
functional basis to the mechanism of action; however, no visible
aggregates or decreases in mutant protein solubility were seen in
HEK293T cells transfected with V5-PFN1E117G. Previous studies
demonstrated formation of insoluble aggregates only with MG132
treatment, and although there was a (nonsignificant) tendency for
the E117G mutant to inhibit neurite outgrowth in primary motor
neuron cultures, there was no affect of the mutation on the inter-
action with actin (Wu et al., 2012). Our modeling of this mutation
predicts there should be a reduced interaction with actin, because
of a loss of hydrogen bonding compared with the native glutamic
acid residue. At this stage, functional and in silico modeling of the
E117G variant has suggested tentative insights into a disruptive
mechanism. At a genetic level however, E117G appears to beoverrepresented in SALS cases compared with FALS in the litera-
ture. This suggests E117G to behave more as a low penetrant, sus-
ceptibility factor and that multiple mutations may be required to
manifest a phenotype in these specific cases, which supports an
oligogenic model of disease (van Blitterswijk et al., 2012a). Exome
sequencing of PFN1 E117G cases might reveal additional and/or
interacting disease susceptibility alleles. In contrast however, the
Q139L variant is novel but does not yield either visible aggregates or
decrease protein solubility, andmodeling of this variant suggests no
effect on the interactionwith actin or VASP or destabilization of the
PFN1 structure. It is plausible that Q139L is a benign private poly-
morphism or alternatively could be involved in as yet unidentified
protein-protein interactions that our assays may not have detected.
Brain tissue was available from 2 ALS patients who carried the
E117G variant (1 FALS and 1 SALS case) and also a sporadic patient
with the Q139L mutation. Neuropathologic examination revealed
the 3 cases to have neuronal and/or glial TDP-43 positive and p62
positive inclusions in the motor cortex or spinal cord, with no PFN1
positive inclusions detected. This confirms previous neuropa-
thology reports of patients with the E117G variant (van Blitterswijk
et al., 2013; Yang et al., 2013). As in vitro studies have failed to
identify any striking cellular phenotypes because of the E117G and
the Q139L mutations, it is perhaps not surprising that the neuro-
pathology of these cases present with a classic TDP-43 proteinop-
athy. It remains to be seen whether the same neuropathologic
signature will be seen in cases with other PFN1 mutants that form
insoluble PFN1 aggregates in vitro.
The identification and characterization of novel PFN1 variants in
patients with ALS adds further support to the hypothesis that these
are causative of disease. These PFN1 variants span a genetic and
pathobiological spectrum from rare, nonaggregant (Q139L), to com-
mon, ALS-associated (E117G), to rare and highly proaggregant (C71G,
A20T). The recruitment of wild-type PFN1 to oligomers of mutant
PFN1 suggests both loss and gain of function mechanisms may be at
play. The cytoskeleton is central to axonal transport and morpho-
genesis, the stress granule response and several other cellular pro-
cesses linked to ALS. As more genetic causes of ALS are identified,
common targets for drug discovery will continue to emerge.
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